Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World StudyHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer|June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Journal of Cancer Research and Clinical Oncology|March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patientsMargherita Rimini, Mara Persano, Toshifumi Tada, et al.
Targeted Oncology|March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
International Journal of Cancer|November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaFederico Rossari, Toshifumi Tada, Goki Suda, et al.
Oncology|January 19, 2023
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.
Pageof 17